Clinical trials
Moderate to Severe Atopic Dermatitis clinical trials
Below are recruiting moderate to severe atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04170244Recruiting
Skin microbiome study in atopic dermatitis and psoriasis
This study looks at the skin’s germs (“microbiome”) in people with atopic dermatitis (eczema) or psoriasis. It may help researchers better understand what’s going on on the skin and how that might relate to disease severity.
Rochester, New YorkAges 13 years+ - NCT05042258RecruitingPhase 4
Dupilumab to improve sleep and itch in children with eczema
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Chicago, IllinoisAges 6–17 - NCT05285839RecruitingPhase 4
Dupixent plus UVB light for moderate to severe eczema
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
East Windsor, New JerseyAges 18 years+ - NCT05391061Recruiting
Cibinqo tablet study for moderate-to-severe atopic dermatitis
This study looks at Cibinqo (an oral medicine) in people with moderate-to-severe atopic dermatitis (eczema) who are already going to start it under their clinician’s standard care plan. It may help doctors learn about how the medicine works and fits into real-world treatment.
SeoulAges 12 years+ - NCT05819463Recruiting
Study care for moderate to severe atopic dermatitis
This trial looks at treatment and medical care for teens and adults with moderate to severe atopic dermatitis (eczema). It may help by testing ways to manage symptoms better based on severity and current treatment needs.
BaselAges 12 years+ - NCT05995964RecruitingPhase 2
Study of two new medicines for eczema
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Birmingham, AlabamaAges 18 years+ - NCT06039241Recruiting
Long-term Dupilumab treatment for atopic dermatitis
This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.
AachenAges 6 years+ - NCT06055361RecruitingPhase 1
Studying a new injection for moderate to severe eczema
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
North Little Rock, ArkansasAges 18 years+ - NCT06311682RecruitingPhase 3
Testing a new shot plus steroid cream for children with eczema
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
Birmingham, AlabamaAges 6 months–11 years - NCT06313333Recruiting
National registry for moderate to severe adult atopic dermatitis
This registry tracks adults with moderate to severe atopic dermatitis (eczema) over time. It helps doctors learn more about the disease and how treatments work in real life.
Brescia, BresciaAges 18 years+ - NCT06397911RecruitingPhase 2
Testing FB825 for moderate to severe eczema
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
Fountain Valley, CaliforniaAges 18–65 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT06587685RecruitingPhase 3
PG-011 gel for eczema in teens and adults
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
Shenyang, LiaoningAges 12–75 - NCT05689151Recruiting
Abrocitinib for adult moderate to severe atopic eczema
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
Amiens, SommeAges 18 years+ - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Birmingham, AlabamaAges 18–63 - NCT06765005RecruitingPhase 1/Phase 2
Study of MG-K10 for Teens with Moderate to Severe Eczema
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
Hangzhou, ZhejiangAges 12–18 - NCT06775860RecruitingPhase 3
Testing ICP-332 for moderate to severe eczema
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hefei, AnhuiAges 18–75 - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+ - NCT06850311RecruitingPhase 2/Phase 3
Herbal ointment for mild to severe eczema
This trial tests whether a special herbal ointment can help treat atopic dermatitis (eczema). It is for adults with mild, moderate, or severe eczema covering less than 10% of their body surface. The ointment is applied directly to the skin, and participants will also use a gentle, fragrance-free moisturizer.
New Taipei CityAges 18–65 - NCT06855745RecruitingPhase 2
Testing a new gel for mild to moderate eczema
This study tests a new gel called Zabalafin Hydrogel to see if it helps people with mild to moderate atopic dermatitis (eczema). The gel is applied directly to the skin. If you or your child has eczema on the head, neck, trunk, or limbs, this trial may be an option.
Brookvale, New South WalesAges 2 years+ - NCT06882148Recruiting
How long do eczema patients stay on targeted therapies?
This study looks at how long people with moderate to severe eczema stay on newer targeted medicines (biologics or pills). By reviewing medical records, researchers hope to learn which treatments work best over time and how they are used in real life.
RomeAges 18 years+ - NCT06906497RecruitingPhase 4
Lebrikizumab for moderate-to-severe eczema
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
Folsom, CaliforniaAges 18 years+ - NCT06946641RecruitingPhase 1
Testing QLS12010 safety in healthy adults and people with eczema
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
BeijingAges 18–75 - NCT06947980RecruitingPhase 2
Study of CM512 for moderate-to-severe atopic dermatitis
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
BeijingAges 18–75
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe atopic dermatitis?
- Yes. Clin2 currently lists 97 recruiting moderate to severe atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.